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Abstract 25 
 26 
Background 27 
This study investigated differences in cognitive performance between middle-aged adults with and without a 28 
lifetime history of mood disorder features, adjusting for a range of potential confounders. 29 
 30 
Methods  31 
Cross-sectional analysis of baseline data from the UK Biobank cohort. Adults aged 40-69 (n=143,828) were 32 
assessed using measures of reasoning, reaction time and memory. Self-reported data on lifetime features of 33 
major depression and bipolar disorder were used to construct groups for comparison against controls. 34 
Regression models examined the association between mood disorder classification and cognitive 35 
performance, adjusting for sociodemographic, lifestyle and clinical confounders. 36 
 37 
Results 38 
Inverse associations between lifetime history of bipolar or severe recurrent depression features and 39 
cognitive performance were attenuated or reversed after adjusting for confounders, including psychotropic 40 
medication use and current depressive symptoms. Participants with a lifetime history of single episode or 41 
moderate recurrent depression features outperformed controls to a small (but statistically significant) 42 
degree, independent of adjustment for confounders. There was a significant interaction between use of 43 
psychotropic medication and lifetime mood disorder features, with reduced cognitive performance observed 44 
in participants taking psychotropic medication. 45 
 46 
Conclusions 47 
In this general population sample of adults in middle age, lifetime features of recurrent depression or bipolar 48 
disorder were only associated with cognitive impairment within unadjusted analyses. These findings 49 
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underscore the importance of adjusting for potential confounders when investigating mood disorder-related 50 
cognitive function.  51 
 52 
Key words Cognition; unipolar depression; mania and bipolar disorder; epidemiology; UK Biobank 53 
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1. Introduction 54 
 55 
Cognitive impairment is a common feature of mood disorders, persisting throughout remission or euthymia, 56 
and contributing to functional disability (1-6). Impairment is typically found on tests of attention, working 57 
and episodic memory, processing speed and executive function, with standardised effect sizes in the 58 
medium range compared to non-mood disordered controls (3-6). Impairments of memory and processing 59 
speed are greater during acute illness episodes than in periods of remission or euthymia, whereas deficits in 60 
attention and executive function are more likely to persist to a similar degree over time (1, 3, 7). It has been 61 
suggested that attention and executive function impairments are endophenotypic features of mood 62 
disorder, reflecting dysfunction of prefrontal brain networks (1, 8), but the influence of confounding factors 63 
on the relationship between mood disorder features and cognition is not well understood. 64 
 65 
A number of demographic and clinical factors have been investigated in association with cognitive 66 
impairment in mood disorder. Older age (either at time of assessment or at illness onset) has been linked 67 
with poorer cognitive performance (1, 6), and history of more than one illness episode has been associated 68 
with greater impairment in some but not all studies (2, 5, 9). The influence of depression severity at time of 69 
assessment (measured by symptom rating scales) is unclear, with studies reporting an association with only 70 
certain cognitive tasks (1, 5); usually memory, speed and executive function. Studies on the effect of 71 
psychotropic medication have produced conflicting results. One study reported an improvement in verbal 72 
memory in patients with major depressive disorder (MDD) who responded to a selective serotonin reuptake 73 
inhibitor (SSRI) antidepressant (10). Another study of SSRI-responsive MDD patients found normal initial 74 
learning performance, but particular difficulties with generalisation of learning from one memory task to 75 
another (11). In a study of older adults with MDD, SSRI responders had minor improvements in visuospatial 76 
function and psychomotor speed from pre- to post-treatment, whereas SSRI non-responders showed 77 
deterioration in psychomotor speed and verbal memory (12). In bipolar disorder, cognitive impairment may 78 
be influenced by antipsychotic medications but not mood stabilisers (13). A recent individual participant data 79 
5 
 
meta-analysis of 2,876 patients with bipolar disorder (5) reported an adverse effect of antipsychotic 80 
medication on one measure of memory, but no effects of lithium, antidepressants or anticonvulsants; 81 
significantly better performance was also seen on memory tasks in the small number of patients who were 82 
drug-free compared with those who were on any psychotropic medication.  83 
 84 
Other characteristics that are known to differ between mood disorder groups and the general population 85 
and which, in themselves, may be associated with variation in cognitive performance, include lifestyle 86 
factors (such as smoking and alcohol intake) and socioeconomic status. While many studies of cognitive 87 
function in mood disorder have adjusted for age, gender and education level, very few have taken account 88 
of other potential lifestyle-related confounders. 89 
 90 
Studies in this field typically use small samples, and meta-analyses are limited by heterogeneity in study 91 
populations, diversity of cognitive measures used, and differences in levels of statistical adjustment. The UK 92 
Biobank project (http://www.ukbiobank.ac.uk/) provides an opportunity to investigate, at scale, the 93 
association of cognitive performance with clinically relevant features of depression and bipolar disorder. The 94 
aims of this cross-sectional analysis were to investigate differences in cognitive performance between UK 95 
Biobank participants with and without a history of depressive and bipolar disorder features, and to examine 96 
whether these differences were independent of a broad range of potential confounders.  97 
 98 
 99 
2. Materials and Methods 100 
 101 
2.1. Participants 102 
Adults aged 40 to 69 years who were registered with the National Health Service and living within 25 miles 103 
of a study assessment centre were invited by mail to participate in UK Biobank. For the purposes of the 104 
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present study, participants were excluded if they self-reported a neurological condition that can affect 105 
cognitive performance (see Appendix S1 in the Supplementary Material for a list of excluded conditions).  106 
 107 
2.2. Measures and procedure 108 
This study was conducted under generic approval from the NHS National Research Ethics Service (Ref. 109 
11/NW/0382). All participants gave written informed consent. Baseline assessments took place at 22 centres 110 
across England, Scotland and Wales between 2006 and 2010. Questionnaires and cognitive assessments 111 
were administered in a standardised order via a computerised touchscreen interface, followed by a face-to-112 
face interview with a research nurse to obtain additional data. Assessment took place in a single visit lasting 113 
approximately 90 minutes.  114 
 115 
2.2.1. Demographic and lifestyle data 116 
The demographic data analysed in the present study included age, gender and neighbourhood-level socio-117 
economic status as measured by the Townsend index of material deprivation (14). Educational qualifications 118 
were recorded, and for the present study were dichotomised according to whether or not participants held a 119 
university degree. Data on smoking status were used to classify participants into three categories (current, 120 
forŵer aŶd Ŷeǀer); the latter tǁo ǁere ĐoŵďiŶed iŶto a ͚ŶoŶ-sŵoker͛ ĐategorǇ for soŵe aŶalǇses. Current 121 
frequency of alcohol consumption ǁas reĐorded ordiŶallǇ oǀer siǆ Đategories froŵ ͚Ŷeǀer͛ to ͚dailǇ/alŵost 122 
dailǇ͛; this was dichotomised to daily/almost daily versus other for some analyses. Current medications were 123 
self-reported to the research nurse, and participants were dichotomised according to whether or not they 124 
were taking any psychotropic medication (mood stabilisers, antidepressants, antipsychotics, sedatives or 125 
hypnotics); Appendix S2 in the Supplementary Material lists these medications.  126 
 127 
2.2.2. Cognitive assessment 128 
Five cognitive measures were administered via computerised touchscreen interface. The total time to 129 
complete all five cognitive tests was approximately 15 minutes. Full details of each measure are provided in 130 
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the Supplementary Material (Methods S1). The tests were designed specifically for UK Biobank, in order to 131 
allow administration at scale without examiner supervision. Briefly, the assessments included: 132 
 Reasoning 133 
This test assessed the ability to solve verbal and numeric reasoning problems. The score was the total 134 
number of correct answers given within a two minute period. 135 
 Reaction time 136 
This task recorded response time to visual stimuli (matching pairs). The score for analysis was the mean 137 
response time in milliseconds. 138 
 Numeric memory 139 
Short term memory was assessed using number strings of increasing length. The score for analysis was the 140 
maximum string length recalled correctly. 141 
 Pairs matching 142 
This task assessed visuospatial memory. Six pairs of symbols were presented on-screen in a random pattern. 143 
The cards were then turned face down on the screen and participants were asked to touch as many pairs as 144 
possible in the fewest tries. The score for analysis was the number of errors made.  145 
 Prospective memory 146 
The ability to remember and act on an instruction after a filled delay was assessed. For the present analyses, 147 
data ǁere diĐhotoŵised as either ͚ĐorreĐt oŶ first atteŵpt͛ or Ŷot. 148 
 149 
2.2.3. Mood disorder features 150 
In the final two years of recruitment, the touchscreen questionnaire included questions about lifetime 151 
experience of depressive and manic symptoms, based on symptoms within the Structured Clinical Interview 152 
for DSM-IV Axis I Disorders (15), in addition to questions about medical help-seeking for mental health. 153 
Responses were used to construct subgroups of participants with clinically significant lifetime features of 154 
bipolar disorder and major depression; criteria are listed in Figure 1. Their validity has been described in 155 
detail by our group previously (16). Participants were grouped according to whether they met our criteria for 156 
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features of each disorder, and were then assigned hierarchically to mutually exclusive categories, such that 157 
any individual meeting criteria for more than one subgroup was classified in the following hierarchical order: 158 
features of bipolar type I or bipolar type II (combined as bipolar disorder), severe recurrent major 159 
depression, moderate recurrent major depression and single episode major depression.  160 
 161 
[Figure 1 about here] 162 
 163 
The remainder of the sample who did not meet the above criteria formed the control group for statistical 164 
analysis. This group included participants with some mild, sub-threshold mood disorder features (shortlived 165 
symptoms of mania, or mild features of depression but without having seen a doctor), in addition to those 166 
with no clinically significant features of mood disorder.  167 
 168 
Current depressive symptoms were assessed by four questions about depressive symptom experience in the 169 
past two weeks: frequency of depressed mood/hopelessness, unenthusiasm/uninterest, 170 
tenseness/restlessness, and tiredness/lethargy. Participants self-rated each symptom on a four-point scale 171 
froŵ ͚Ŷot at all͛ (scoring 0) to ͚ŶearlǇ eǀerǇ daǇ͛ (scoring 3), summated to produce an overall score ranging 172 
from 0 to 12, with higher scores indicating more depressive symptoms during the preceding two weeks. 173 
Neuroticism was assessed using 12 yes/no questions from the Eysenck Personality Questionnaire Revised 174 
Neuroticism scale (17), producing a total score ranging from 0 to 12, with higher scores indicating greater 175 
neuroticism.  176 
 177 
2.3. Statistical analysis 178 
Associations between lifetime features of mood disorder and cognitive performance were tested using a 179 
series of regression models, with successive adjustment for confounders (see Methods S2 in the 180 
Supplementary Material for details). Regression results are reported as unstandardised coefficients, 181 
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incidence rate ratios (IRR) or odds ratios (OR), with 95% confidence intervals (CI). Statistical significance was 182 
defined conservatively as p<0.01. All analyses were performed using Stata version 12.1 (18).  183 
 184 
 185 
3. Results 186 
 187 
3.1. Composition and characteristics of the study participants  188 
There was a response rate of approximately 6% to the study invitations (19). Of 172,745 participants who 189 
were assessed with regard to lifetime depressive and manic symptoms, 149,843 (86.7%) provided sufficient 190 
data to allow classification into subgroups according to presence or absence of clinically significant mood 191 
disorder features. Participants self-reporting a history of neurological disorder that can impair cognition 192 
(n=6,015; 4.0%) were excluded, leaving a study population of 143,828.  193 
 194 
Of these, 1,521 (1.1%) met criteria for features of bipolar disorder; 8,354 (5.8%) for severe recurrent major 195 
depression; 14,386 (10.0%) for moderate recurrent major depression and 7,607 (5.3%) for a single episode 196 
of major depression. The remaining 111,960 (77.8%) formed the control group. Of these, 86,190 had no 197 
clinically significant mood disorder features (narrow control group), 23,384 had depressive symptoms that 198 
did not fulfil the criteria and 2,386 had manic symptoms that did not fulfil the criteria. Figure S1 in the 199 
Supplementary Material shows a flowchart of the sample composition. 200 
 201 
Table 1 shows the demographic, lifestyle and psychological characteristics of the sample. Characteristics 202 
were very similar between the wide and narrow control groups (see Table 2), and so the results from the 203 
wide control group (including those with subthreshold mood disorder features) will be the focus here. The 204 
youngest group was the bipolar disorder group, who were approximately 2.7 years younger than the control 205 
group. Compared with the control group, women were over-represented in the three major depression 206 
groups but not in the bipolar group. A disproportionate number within the bipolar and severe recurrent 207 
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depression groups were at the more deprived end of the socioeconomic distribution, based on Townsend 208 
score quintiles, but the proportion holding a degree qualification was slightly higher for all mood disorder 209 
groups than for the control group. The prevalence of smoking was highest in the bipolar group and lowest in 210 
the control group, with evidence of a gradient across the groups according to severity of mood disorder. 211 
Conversely, abstention from alcohol was highest in the bipolar and severe recurrent depression groups. 212 
 213 
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Table 1. Sample characteristics, by lifetime mood disorder features 214 
 215 
 Bipolar disorder 
n = 1521 
Recurrent major 
depression (severe) 
n = 8354 
Recurrent major 
depression 
(moderate) 
n = 14 386 
Single episode major 
depression 
n = 7607 
Control
 
n = 111 960 
Test 
statistic 
df p value
 
Age
a
 mean (SD), years
 
54.28 (8.08) 55.56 (8.06) 55.35 (7.93) 56.24 (8.02) 56.96 (8.20) 204.79
b
 4, 143 823 <.001 
Gender
a
 female n (%)
 
745 (49.0) 4846 (58.0) 9940 (69.1) 4860 (63.9) 56 517 (50.5) 2200
c
 4 <.001 
Townsend score quintile         
Missing data n 1 17 29 19 169    
1 (least deprived) n (%) 162 (10.7) 1098 (13.2) 2273 (15.8) 1283 (16.9) 19 071 (17.1)    
2 196 (12.9) 1330 (16.0) 2769 (19.3) 1553 (20.5) 22 721 (20.3)    
3 258 (17.0) 1561 (18.7) 2952 (20.6) 1615 (21.3) 23 238 (20.8) 781.78
c
 16 <.001 
4 373 (24.5) 1959 (23.5) 3268 (22.8) 1767 (23.3) 25 016 (22.4)    
5 (most deprived) 531 (34.9) 2389 (28.7) 3095 (21.6) 1370 (18.1) 21 745 (19.5)    
Educated to degree level         
Missing data n 11 61 85 38 1107    
Yes n (%) 546 (36.2) 3044 (36.7) 5029 (35.2) 2792 (36.9) 38 356 (34.6) 30.90
c
 4 <.001 
Smoking status         
Missing data n 2 5 2 5 43    
Current n (%) 322 (21.2) 1392 (16.7) 1655 (11.5) 787 (10.4) 9809 (8.8)    
Former 534 (35.2) 3113 (37.3) 5203 (36.2) 2821 (37.1) 37 716 (33.7) 1100
c
 8 <.001 
Never 663 (43.7) 3844 (46.0) 7526 (52.3) 3994 (52.5) 64 392 (57.5)    
Alcohol frequency         
Missing data n 3 7 4 4 61    
Daily/almost daily n (%) 299 (19.7) 1676 (20.1) 2792 (19.4) 1546 (20.3) 23 376 (20.9)    
3-4 times per week 258 (17.0) 1597 (19.1) 3112 (21.6) 1813 (23.9) 26 311 (23.5)    
1-2 times per week 344 (22.7) 1808 (21.7) 3572 (24.8) 1933 (25.4) 28 721 (25.7) 633.50
c
 20 <.001 
1-3 times per month 191 (12.6) 1036 (12.4) 1911 (13.3) 924 (12.2) 12 182 (10.9)    
Special occasions only 228 (15.0) 1204 (14.4) 1900 (13.2) 861 (11.3) 12 579 (11.2)    
Never 198 (13.0) 1026 (12.3) 1095 (7.6) 526 (6.9) 8730 (7.8)    
On psychotropic 
medication 
  
 
 
 
     
Missing data n 24 95 190 118 1312    
Yes n (%) 464 (31.0) 2791 (33.8) 2550 (18.0) 587 (7.8) 3186 (2.9) 16 000
c
 4 <.001 
Current depressive 
symptoms score (0-12) 
 
 
 
 
 
 
 
 
 
 
   
 
Missing data n 119 647 1051 529 9405    
Median (25
th
, 75
th
 %ile) 3 (1, 5) 2 (1, 4) 2 (1, 4) 1 (0, 2) 1 (0, 2) 9478.18
d
 4 <.001 
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 Bipolar disorder 
n = 1521 
Recurrent major 
depression (severe) 
n = 8354 
Recurrent major 
depression 
(moderate) 
n = 14 386 
Single episode major 
depression 
n = 7607 
Control
 
n = 111 960 
Test 
statistic 
df p value
 
Neuroticism score (0-12)         
Missing data n 304 1372 2356 1107 18 575    
Mean (SD) 6.56 (3.58) 6.80 (3.39) 5.78 (3.18) 4.15 (2.99) 3.38 (2.93) 3769.96
b
 4, 120 109 <.001 
 216 
SD, standard deviation. 217 
a. No missing data. 218 
b. One-way ANOVA. 219 
c. Pearson χ2 test. 220 
d. Kruskal-Wallis test. 221 
 222 
 223 
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Table 2. Sample characteristics and cognitive performance in the wide and narrow control groups 224 
 225 
 Wide control group
a 
n = 111 960 
Narrow control group
b 
n = 86 190 
Age
c
 mean (SD), y
 
56.96 (8.20) 57.29 (8.12) 
Female
c
 n (%)
 
56 517 (50.5) 43 162 (50.1) 
Townsend score quintile   
Missing data n 169 134 
1 (least deprived) n (%) 19 071 (17.1) 15 029 (17.5) 
2 22 721 (20.3) 17 764 (20.6) 
3 23 238 (20.8) 17 990 (20.9) 
4 25 016 (22.4) 18 970 (22.0) 
5 (most deprived) 21 745 (19.5) 16 303 (18.9) 
Educated to degree level   
Missing data n  1107 910 
Yes n (%) 38 356 (34.6) 28 671 (33.6) 
Smoking status   
Missing data n  43 34 
Current n (%) 9809 (8.8) 7106 (8.3) 
Former 37 716 (33.7) 28 878 (33.5) 
Never 64 392 (57.5) 50 172 (58.2) 
Alcohol frequency   
Missing data n  61 45 
Daily/almost daily n (%) 23 376 (20.9) 18 083 (21.0) 
3-4 times per week 26 311 (23.5) 20 410 (23.7) 
1-2 times per week 28 721 (25.7) 22 068 (25.6) 
1-3 times per month 12 182 (10.9) 9119 (10.6) 
Special occasions 12 579 (11.2) 9662 (11.2) 
Never 8730 (7.8) 6803 (7.9) 
On psychotropic medication   
Missing data n  1312 1003 
Yes n (%) 3186 (2.9) 2467 (2.9) 
Current depressive symptoms score (0-12)   
Missing data n  9405 7464 
Median (25
th
, 75
th
 %ile) 1 (0, 2) 1 (0, 2) 
Neuroticism score (0-12)   
Missing data n  18 575 14 563 
Mean (SD) 3.38 (2.93) 3.25 (2.90) 
Reasoning score (0-13)   
Missing data n  3835 3151 
Mean (SD) 6.03 (2.16) 6.02 (2.16) 
Reaction time (ms)   
Missing data n  1225 1012 
Median (25
th
, 75
th
 %ile) 543 (484, 621) 546 (485, 622) 
Numeric memory score (2-12)    
Missing data
d
 n
  
817 659 
Mean (SD) 6.71 (1.34) 6.70 (1.33) 
Pairs matching (errors)
c
   
Median (25
th
, 75
th
 %ile) 3 (2, 5) 3 (2, 5) 
Prospective memory   
Missing data n  568 483 
Correct 1
st
 attempt n (%) 85 724 (77.0) 65 505 (76.4) 
 226 
SD, standard deviation. 227 
a. Full control group, including participants with no clinically significant mood disorder features, sub-threshold bipolar features 228 
or sub-threshold depressive features. 229 
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b. Subgroup restricted to participants with no clinically significant mood disorder features. 230 
c. No missing data. 231 
d. The Numeric Memory task was removed from the baseline battery before recruitment ended; missing data refers only to the 232 
period when this task was included in the battery. 233 
 234 
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Group differences were evident on the current depressive symptoms score, with the bipolar group 235 
having the highest median score and the single episode depression and control groups having the 236 
lowest. The severe recurrent depression group had a slightly higher mean neuroticism score than the 237 
bipolar group, with mean scores then reducing across the other groups. 238 
 239 
3.2. Cognitive performance across groups 240 
Table 3 shows the performance of each group on the five cognitive outcome measures. The single 241 
episode depression group performed best across all measures, followed by the moderate recurrent 242 
depression group and the control group. The severe recurrent depression and bipolar groups 243 
showed the poorest performance. Cognitive performance was very similar between the wide and 244 
narrow control groups (see Table 2). 245 
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Table 3. Cognitive performance, by lifetime mood disorder features 246 
 247 
 Bipolar disorder 
n = 1521 
Recurrent major 
depression 
(severe) 
n = 8354 
Recurrent major 
depression 
(moderate) 
n = 14 386 
Single episode 
major depression 
n = 7607 
Control
 
n = 111 960 
Test statistic df p value
 
Reasoning score (0-13)         
Missing data n 65 320 320 148 3835    
Mean (SD) 5.76 (2.24) 5.91 (2.22) 6.11 (2.08) 6.30 (2.08) 6.03 (2.16) 45.24 4, 139 135 <.001
a
 
Reaction time (ms)         
Missing data n 21 101 108 38 1225    
Median (25
th
, 75
th
 %ile) 547 (483, 620) 543 (484, 625) 540 (480, 614) 539 (480, 613) 543 (484, 621) 40.53 4 <.001
b
 
Numeric memory score (2-12)          
Missing data
c
 n
  
14 81 108 40 817    
Mean (SD) 6.62 (1.45) 6.63 (1.40) 6.71 (1.28) 6.78 (1.30) 6.71 (1.34) 4.26 4, 42 240 .002
a
 
Pairs matching (errors)
d 
        
Median (25
th
, 75
th
 %ile) 3 (2, 6) 3 (2, 6) 3 (2, 5) 3 (2, 5) 3 (2, 5) 24.93 4 <.001
b
 
Prospective memory         
Missing data n 11 48 49 16 568    
Correct 1
st
 attempt n (%) 1113 (73.7) 6252 (75.3) 11 381 (79.4) 6246 (82.3) 85 724 (77.0) 180.91 4 <.001
e
 
 248 
SD, standard deviation. 249 
a. One-way ANOVA. 250 
b. Kruskal-Wallis test. 251 
c. The Numeric Memory task was removed from the baseline battery before recruitment ended; missing data refers only to the period when this task was included in the battery.  252 
d. No missing data. 253 
e. Pearson χ2 test. 254 
 255 
 256 
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3.3. Association between cognitive performance and other variables 257 
In the sample as a whole, statistically significant associations of generally small effect size were 258 
found between performance on cognitive tests and demographic, lifestyle and psychological 259 
variables (see Results S1 in the Supplementary Material for details).  260 
 261 
3.4. Relationship between cognitive function and lifetime features of mood disorder 262 
Due to the strong correlation between the current depressive symptoms score and the neuroticism 263 
score (ρ=0.534, p<0.001), only the former was included as a covariate in the regression analyses. The 264 
results of the unadjusted and fully adjusted regression models for the five cognitive measures are 265 
shown in Table 4. Table S1 in the Supplementary Material gives detailed results for each successive 266 
stage of the model adjustment. When the models were re-run using the narrow control group, the 267 
results were virtually identical with respect to the magnitude, direction and statistical significance of 268 
the coefficients, and so only the results using the wide control group are reported here. Model 269 
results using the raw and log-transformed reaction time data were very similar, and so the results 270 
using the raw data are presented for ease of interpretation. 271 
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Table 4. Regression models for the association between lifetime mood disorder features and cognitive performance  272 
 273 
 Unadjusted model
 
Fully adjusted model
a 
 Coefficient (95% CI) p value Coefficient (95% CI) p value 
Reasoning score
b 
n = 139 140  n = 125 789  
Single episode major depression 0.27 (0.23, 0.31) <.001 0.26 (0.22, 0.31) <.001 
Recurrent major depression (moderate) 0.08 (0.05, 0.12) <.001 0.22 (0.18, 0.26) <.001 
Recurrent major depression (severe) -0.12 (-0.17, -0.07) <.001 0.12 (0.07, 0.17) <.001 
Bipolar disorder -0.27 (-0.38, -0.17) <.001 0.04 (-0.06, 0.13) .442 
Reaction time (ms)
b 
n = 142 335  n = 128 104  
Single episode major depression -6.59 (-9.41, -3.77) <.001 -5.47 (-8.19, -2.75) <.001 
Recurrent major depression (moderate) -4.96 (-7.11, -2.81) <.001 -6.24 (-8.29, -4.20) <.001 
Recurrent major depression (severe) 4.12 (1.52, 6.72) .002 -0.82 (-3.40, 1.75) .530 
Bipolar disorder 2.37 (-5.28, 10.02) .543 1.70 (-5.11, 8.51) .625 
Numeric memory score
b
  n = 42 245
c 
 n = 38 051
c 
 
Single episode major depression 0.07 (0.01, 0.13) .015 0.07 (0.02, 0.12) .004 
Recurrent major depression (moderate) 0.00 (-0.04, 0.04) .868 0.06 (0.02, 0.11) .004 
Recurrent major depression (severe) -0.08 (-0.14, -0.02) .006 0.02 (-0.04, 0.08) .505 
Bipolar disorder -0.10 (-0.26, 0.07) .267 0.03 (-0.10, 0.16) .606 
 IRR (95% CI) p value IRR (95% CI) p value 
Pairs matching (errors)
d 
n = 143 828  n = 129 229  
Single episode major depression 0.97 (0.95, 0.98) <.001 0.98 (0.96, 0.99) .009 
Recurrent major depression (moderate) 0.98 (0.97, 0.99) .023 0.99 (0.98, 1.01) .428 
Recurrent major depression (severe) 1.04 (1.02, 1.06) <.001 1.03 (1.02, 1.05) <.001 
Bipolar disorder 1.04 (0.99, 1.08) .085 1.04 (0.99, 1.08) .095 
 OR (95% CI) p value OR (95% CI) p value 
Prospective memory (correct 1
st
 attempt)
e 
n = 143 136  n = 128 727  
Control group (reference) 1 - 1 - 
Single episode major depression 1.39 (1.31, 1.48) <.001 1.37 (1.28, 1.47) <.001 
Recurrent major depression (moderate) 1.15 (1.10, 1.20) <.001 1.25 (1.19, 1.31) <.001 
Recurrent major depression (severe) 0.91 (0.87, 0.96) <.001 1.11 (1.05, 1.18) .001 
Bipolar disorder 0.84 (0.75, 0.94) .003 1.05 (0.92, 1.19) .501 
 274 
CI, confidence interval; IRR, incidence rate ratio; OR, odds ratio. 275 
a. Full model adjusted for age, gender, current smoker, alcohol daily/almost daily, on psychotropic medication, current depressive symptoms score, has a degree, Townsend score. 276 
b. Linear regression with bootstrapped standard errors; omitted reference group was the control group. 277 
c. The Numeric Memory task was removed from the baseline battery before recruitment ended, yielding smaller possible sample sizes than for the other cognitive measures. 278 
d. Negative binomial regression; omitted reference group was the control group. 279 
e. Logistic regression. 280 
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3.4.1. Reasoning 281 
 The fully adjusted model indicated that all three major depression groups were outperforming 282 
controls, and the bipolar group was no longer significantly different from controls. The magnitude of 283 
the effect of group membership on performance compared to controls in the fully adjusted model 284 
was small, being no larger than an increase of a quarter of a point on a 0-13 point scale, seen in the 285 
single episode depression group.  286 
 287 
3.4.2. Reaction time 288 
In the fully adjusted model, the single episode and moderate recurrent depression groups were 289 
significantly faster than controls and the other groups were not significantly different from controls. 290 
Effect sizes were small, with the single episode and moderate recurrent depression groups being 291 
approximately 6ms faster than the control group in the fully adjusted model.  292 
 293 
3.4.3. Numeric memory 294 
The fully adjusted model suggested that performance was significantly better in the single episode 295 
and moderate recurrent depression groups, although this effect was small, representing a gain of 296 
less than a tenth of a point on a scale which ranges from 2 to 12. Performance in the other groups 297 
was no different from controls.  298 
 299 
3.4.4. Pairs matching 300 
The fully adjusted model indicated fewer errors in the single episode depression group and more 301 
errors in the severe recurrent depression group compared to controls, but the other groups were 302 
not significantly different from controls. Magnitude of effect of group membership was small (IRR of 303 
errors in the severe recurrent depression group versus controls = 1.03; 95% CI 1.02, 1.05). In 304 
contrast to the other cognitive measures, adjusting for confounders did not lead to notable changes 305 
in the effect sizes across successive models for each mood group on this measure.  306 
 307 
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3.4.5. Prospective memory 308 
Following full adjustment, performance was significantly better than controls in the three major 309 
depression groups, and the bipolar group was not significantly different. Similar to the findings for 310 
the other cognitive measures, the magnitude of effect of group membership was modest (OR for 311 
correct response in single episode depression group versus controls = 1.37; 95% CI 1.28, 1.47).  312 
 313 
3.5. Interaction between lifetime mood disorder status and psychotropic medication  314 
A significant interaction was found between mood disorder group and current use of psychotropic 315 
medication in predicting cognitive performance. Table 5 shows the results of the fully adjusted 316 
regression models, stratified by use of psychotropic medication. For each cognitive measure, the 317 
overall better performance observed for the single episode depression group was driven by those 318 
not taking psychotropic medication and was absent in participants who reported being on 319 
psychotropic medication. Furthermore, although the bipolar group was not significantly different 320 
from controls on any cognitive measure in the overall analyses, the stratified models revealed that 321 
those taking psychotropic medication performed significantly worse than controls on two measures 322 
(reaction time and pairs matching). In the case of reaction time, participants with bipolar features 323 
who were on psychotropic medication were 24ms slower than controls, whereas those not on 324 
medication were 7ms faster. The pattern across most cognitive measures was that use of 325 
psychotropic medication attenuated any cognitive advantage in the milder depression groups, or 326 
worsened any disadvantage in the severe depression and bipolar groups; there was also greater 327 
variance in the groups taking psychotropic medication, which may partly be due to smaller sample 328 
sizes. An exception to this pattern of performance was the reasoning measure, on which the use of 329 
psychotropic medication slightly strengthened the better performance of the moderate and severe 330 
recurrent depression groups.  331 
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Table 5. Regression models for the association between lifetime mood disorder features and cognitive performance, stratified by use of psychotropic medication 332 
 333 
 On psychotropic medication
a 
Not on psychotropic medication
a 
 Coefficient (95% CI) p value Coefficient (95% CI) p value 
Reasoning score
b 
n = 8272  n = 117 517  
Single episode major depression 0.05 (-0.14, 0.25) .582 0.28 (0.23, 0.34) <.001 
Recurrent major depression (moderate) 0.29 (0.19, 0.40) <.001 0.21 (0.17, 0.25) <.001 
Recurrent major depression (severe) 0.20 (0.08, 0.32) .001 0.09 (0.03, 0.16) .005 
Bipolar disorder 0.17 (-0.04, 0.38) .110 -0.02 (-0.14, 0.11) .814 
Reaction time (ms)
b 
n = 8494  n = 119 610  
Single episode major depression -3.35 (-14.96, 8.26) .572 -5.56 (-8.17, -2.96) <.001 
Recurrent major depression (moderate) -6.17 (-12.90, 0.57) .073 -5.62 (-8.70, -2.54) <.001 
Recurrent major depression (severe) 6.93 (-0.25, 14.11) .058 -2.92 (-6.81, 0.97) .141 
Bipolar disorder 23.72 (11.20, 36.23) <.001 -6.82 (-12.98, -0.66) .030 
Numeric memory score
b
  n = 2636
c 
 n = 35 415
c 
 
Single episode major depression 0.03 (-0.19, 0.25) .786 0.07 (0.02, 0.13) .013 
Recurrent major depression (moderate) 0.14 (-0.01, 0.30) .069 0.05 (0.01, 0.09) .024 
Recurrent major depression (severe) 0.12 (-0.04, 0.27) .132 0.00 (-0.07, 0.06) .885 
Bipolar disorder 0.00 (-0.34, 0.35) .983 0.07 (-0.06, 0.21) .307 
 IRR (95% CI) p value IRR (95% CI) p value 
Pairs matching (errors)
d 
n = 8607  n = 120 622  
Single episode major depression 1.01 (0.94, 1.09) .734 0.97 (0.95, 0.99) .005 
Recurrent major depression (moderate) 0.99 (0.95, 1.04) .715 0.00 (0.98, 1.01) .683 
Recurrent major depression (severe) 1.07 (1.02, 1.11) .003 1.03 (1.00, 1.05) .025 
Bipolar disorder 1.13 (1.04, 1.22) .003 0.00 (0.95, 1.05) .916 
 OR (95% CI) p value OR (95% CI) p value 
Prospective memory (correct 1
st
 attempt)
e 
n = 8551  n = 120 176  
Control group (reference) 1 - 1 - 
Single episode major depression 1.13 (0.90, 1.41) .296 1.40 (1.30, 1.50) <.001 
Recurrent major depression (moderate) 1.21 (1.06, 1.38) .004 1.25 (1.18, 1.31) <.001 
Recurrent major depression (severe) 1.01 (0.89, 1.15) .898 1.13 (1.05, 1.21) .001 
Bipolar disorder 0.85 (0.68, 1.07) .177 1.11 (0.95, 1.31) .183 
 334 
CI, confidence interval; IRR, incidence rate ratio; OR, odds ratio. 335 
a. Full model adjusted for age, gender, current smoker, alcohol daily/almost daily, current depressive symptoms score, has a degree, Townsend score. 336 
b. Linear regression with bootstrapped standard errors; omitted reference group was the control group. 337 
c. The Numeric Memory task was removed from the baseline battery before recruitment ended, yielding smaller possible sample sizes than for the other cognitive measures. 338 
d. Negative binomial regression; omitted reference group was the control group. 339 
e. Logistic regression. 340 
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3.6. Effect of missing data 341 
Results across all stages of model adjustment were similar when the analyses were re-run including 342 
only those participants with complete data on all variables required for the final model (Model 5), 343 
indicating that the differences between initial and final models reported above were not simply 344 
driven by participants who contributed data to the unadjusted models but were missing from the 345 
fully adjusted analyses.  346 
 347 
 348 
4. Discussion 349 
 350 
These findings describe associations of cognitive performance with mood disorder features in a non-351 
clinical population and over a range of disorders and severity, and may be contrasted with studies 352 
focussing on clinical populations. These data suggest that for mild mood disorder there is no 353 
detectable cognitive impairment at the group level, other than that associated with psychotropic 354 
medication. 355 
 356 
Across all cognitive measures, the reduced performance compared to controls observed in the 357 
participants with a lifetime history of bipolar or severe recurrent depression features was 358 
attenuated or reversed after adjustment for confounders. Much of the attenuation followed 359 
adjustment for psychotropic medication use, alcohol consumption and smoking, as well as severity 360 
of current depressive symptoms. A different pattern of performance was evident for the groups with 361 
a lifetime history of single episode or moderate recurrent depression features: these participants 362 
slightly outperformed the controls on most cognitive measures, and this effect was stable or 363 
strengthened after adjustment for confounders. An interaction effect was observed between 364 
lifetime mood disorder features and use of psychotropic medication, such that current use of 365 
psychotropic medication attenuated any cognitive advantage in the single episode and moderate 366 
recurrent depression groups, or worsened any disadvantage in those with severe recurrent 367 
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depression or bipolar features. Effect sizes in the adjusted regression models were small and unlikely 368 
to be clinically significant.  369 
 370 
It is likely that mood disorder features are highly heterogeneous in the general population, covering 371 
a broad range of symptom experience and disability. A substantial proportion will not come to the 372 
attention of mental health services and will not be included in clinic-based studies of cognition. It 373 
may therefore be the case that much clinic-based research is not representative of the abilities and 374 
functioning of a large sector of the general population who are living with, or have past experiences 375 
of, mild to moderate features of mood disorder. Variation in cognitive performance within clinic-376 
based samples also merits greater attention, with two recent studies showing that almost one-third 377 
of affectively stable bipolar disorder patients were indistinguishable from healthy controls on 378 
neurocognitive measures (20, 21). It is therefore apparent that the cognitive phenotype associated 379 
with mood disorder is diverse, both in clinical settings and in the broader population. It may be that, 380 
even after adjustment for confounding factors, summary measures of group-level performance on 381 
cognitive tests mask wide variation across participants. Some sub-groups of patients will show 382 
prominent cognitive impairment as part of the depression or bipolar syndrome, while others are 383 
cognitively resilient. We therefore do not believe that cognitive impairment should be dismissed as a 384 
key feature of affective disorders, despite our study findings, but rather suggest that careful 385 
consideration be given to issues of heterogeneity and confounding when considering the presence 386 
of cognitive dysfunction in mood disorder populations. 387 
 388 
Several explanations may be offered for the slightly better performance found in the milder 389 
depression groups relative to controls. The apparent cognitive advantage in these groups may be 390 
artefactual. Possible explanations include differential selection, differential recall or residual 391 
confounding. Differential selection might operate through invitees with mild mood disorder being 392 
more likely to respond than those of comparable ability without mood disorder. Differential recall 393 
bias might be operating through cognitive performance being associated with greater ability and/or 394 
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motivation to recall or report an episode of mood disorder, or with different interpretation of the 395 
questionnaire leading to classification bias (22). Alternatively, higher cognitive ability might  be 396 
associated with differential help-seeking or clinical course among people who have experienced 397 
depression: if higher ability were associated with reduced likelihood of psychiatric healthcare input 398 
then those who did experience recurrent depression would have been classified as moderate rather 399 
than severe by our criteria; or if higher ability were protective in some way against recurrence of 400 
depression then such people would be over-represented in the single episode group. Finally, despite 401 
the wide range of variables analysed here, as with all observational studies, there is a possibility of 402 
residual confounding. 403 
 404 
Use of psychotropic medication was associated with worse cognitive performance, even after 405 
adjustment for other variables. This is congruent with previous research (5, 11-13). It may be that 406 
this relationship is indirect, with use of psychotropic medication being a proxy for mood disorder 407 
severity. If a direct relationship exists, it is unclear what the mechanism might be; certain 408 
medications might have sedative or anticholinergic effects, or may contribute to adiposity and 409 
associated cardiometabolic problems which in turn increase the risk of cognitive impairment.  410 
 411 
The unique strength of this study is that it has assessed the relationship between lifetime features of 412 
mood disorder and cognitive performance in a large population sample. The use of standardised 413 
procedures and outcome measures across study sites represents a significant advantage over 414 
previous studies that have relied on sample aggregation or meta-analytic methods to achieve 415 
statistical power. Unlike other studies in this field, it has been possible to take into account a wide 416 
range of potential confounding variables, also measured in a standard way. Robust multivariate 417 
analysis methods were used, including testing for interactions. The classification of participants 418 
across the severity spectrum from single depressive episode to recurrent depression and bipolar 419 
disorder has alloǁed us to deliŶeate differeŶtial effeĐts ďetǁeeŶ groups aŶd to iŶǀestigate ͚dose-420 
respoŶse͛ assoĐiatioŶs ďetǁeeŶ ŵood disorder seǀeritǇ aŶd ĐogŶitiǀe perforŵaŶĐe.  421 
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 422 
Limitations in the data included lack of access to clinical records including healthcare service use, 423 
and the brevity and self-report nature of mood measurement. We have previously described the 424 
validity of the mood disorder criteria used (16), however, and scores on measures such as the 425 
neuroticism scale successfully differentiated the various groups in accordance with what would be 426 
expected from the clinical literature. The cognitive assessment battery was brief in comparison to a 427 
typical clinical neuropsychological assessment; it did not include classic tests of learning and delayed 428 
memory; and it used bespoke tasks which are not directly comparable to standard clinical measures 429 
routinely used in clinical neuropsychology practice and research. The pattern of findings across the 430 
five different cognitive measures was consistent, however. The presence of missing data on the 431 
covariates reduced the sample size at each successive stage of regression model adjustment, 432 
although results were similar when analyses were repeated using only participants who provided 433 
complete data on all variables. The sample was aged between 40 and 69 years and so findings may 434 
not be extrapolated beyond this age range. The associations were based on cross-sectional data and 435 
so cannot address questions of causality and temporal relationships, but they provide a useful basis 436 
for future longitudinal analyses. 437 
 438 
Future prospective work in UK Biobank will use repeat assessments and linked routine healthcare 439 
data to investigate a range of long-term outcomes. It will be possible to investigate whether baseline 440 
measures of cognition and other characteristics predict incident mood disorder in the control 441 
participants, or recurrence of mood disorder in those who have had a single episode of depression. 442 
There is potential for a range of studies of cognitive function and mood disorder incorporating other 443 
ongoing UK Biobank assessments including neuroimaging, genotyping and biochemical assays. In 444 
particular, we will be able to examine the role of genetic markers alongside the covariates analysed 445 
in this study, to elucidate mediating and moderating effects of genetic and environmental factors in 446 
order to understand the wide variation in cognitive functioning among people with mood disorders. 447 
The present study contributes important knowledge about the multifactorial nature of mood 448 
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disorder-related cognitive function, and lays a foundation for future research which will increase our 449 
understanding in this area. 450 
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Figure legend 461 
 462 
Figure 1. Mood status criteria 463 
Criteria for hierarchical classification of the sample according to self-reported lifetime features of 464 
major depression or bipolar disorder 465 
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 Criteria for lifetime experience of features of bipolar disorder 
 
Bipolar disorder, type I 
Ever ‘manic or hyper’ for 2 days OR ever ‘irritable/argumentative’ for 2 days; plus at least 3 features from ‘more active’, ‘more 
talkative’, ‘needed less sleep’ and ‘more creative/more ideas’; plus duration of a week or more; plus ‘needed treatment or 
caused problems at work’. 
 
Bipolar disorder, type II 
Ever ‘manic or hyper’ for 2 days OR ever ‘irritable/argumentative’ for 2 days; plus at least 3 features from ‘more active’, ‘more 
talkative’, ‘needed less sleep’ and ‘more creative/more ideas’; plus duration of a week or more. 
 
 
Criteria for lifetime experience of features of major depression 
 
Probable recurrent major depression (severe) 
Ever depressed/down for a whole week; plus at least two weeks duration; plus at least two episodes; plus ever seen a 
psychiatrist for ‘nerves, anxiety, tension, depression’ OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at 
least two weeks duration; plus at least two episodes; plus ever seen a psychiatrist for ‘nerves, anxiety, tension, depression’. 
 
Probable recurrent major depression (moderate) 
Ever depressed/down for a whole week; plus at least two weeks duration; plus at least two episodes; plus ever seen a GP (but 
not a psychiatrist) for ‘nerves, anxiety, tension, depression’ OR ever anhedonic (unenthusiasm/uninterest) for a whole week; 
plus at least two weeks duration; plus at least two episodes; plus ever seen a GP (but not a psychiatrist) for ‘nerves, anxiety, 
tension, depression’. 
 
Single probable episode of major depression 
Ever depressed/down for a whole week; plus at least two weeks duration; plus only one episode; plus ever seen a GP or a 
psychiatrist for ‘nerves, anxiety, tension, depression’ OR ever anhedonic (unenthusiasm/uninterest) for a whole week; plus at 
least two weeks duration; plus only one episode; plus ever seen a GP or a psychiatrist for ‘nerves, anxiety, tension, 
depression’. 
 
 
Appendix S1. List of neurological conditions recorded in the UK Biobank dataset (self-
reported by participants; from data fields 6150, 20001 and 20002). 
 
Brain cancer/primary malignant tumour 
Brain haemorrhage 
Brain/intracranial abscess 
Cerebral aneurysm 
Cerebral palsy 
Chronic/degenerative neurological problem 
Dementia/Alzheimer's disease/cognitive impairment 
Encephalitis 
Epilepsy 
Head injury 
Infection of nervous system 
Ischaemic stroke 
Meningeal cancer/malignant meningioma 
Meningioma (benign) 
Meningitis 
Motor neurone disease 
Multiple sclerosis 
Neurological injury/trauma 
Neuroma (benign) 
Other demyelinating condition 
Other neurological problem 
Parkinson's disease 
Spina bifida 
Stroke 
Subarachnoid haemorrhage 
Subdural haematoma 
Transient ischaemic attack 
Appendix S2. List of psychotropic medications recorded in the UK Biobank dataset (self-reported by participants; from data field 20003). 
 
Mood stabiliser Anti-depressant 
(SSRI) 
Anti-depressant  
(other) 
Anti-psychotic  
(traditional) 
Anti-psychotic  
(2nd generation) 
Sedative/hypnotic 
lithium product 
Priadel (lithium) 
Camcolit (lithium) 
sodium valproate 
Epilim (sodium valproate) 
Depakote (semisodium 
valproate) 
valproic acid  
carbamazepine product 
carbamazepine 
Tegretol (carbamazepine) 
Teril (carbamazepine) 
Teril retard (carbamazepine) 
Timonil retard 
(carbamazepine) 
Epimaz (carbamazepine) 
paroxetine 
Seroxat (paroxetine) 
fluoxetine 
Prozac (fluoxetine) 
citalopram 
Cipramil (citalopram)  
escitalopram 
Cipralex 
(escitalopram) 
sertraline 
Lustral (sertraline)  
fluvoxamine 
mirtazapine 
Zispin (mirtazapine) 
duloxetine 
Cymbalta (duloxetine) 
Yentreve (duloxetine)  
venlafaxine 
Efexor (venlafaxine) 
amitriptyline 
Elavil (amitriptyline)  
Tryptizol (amitriptyline) 
Lentizol (amitriptyline)  
amitriptyline+perphenazine 
Triptafen (amitriptyline+perphenazine) 
amitriptyline+chlordiazepoxide 
Limbitrol 10 
(amitriptyline+chlordiazepoxide) 
Limbitrol-5 
(amitriptyline+chlordiazepoxide) 
phenelzine 
maoi - phenelzine 
Nardil (phenelzine) 
moclobemide 
Manerix (moclobemide) 
imipramine 
Tofranil (imipramine) 
trimipramine 
Surmontil (trimipramine) 
dothiepin 
dosulepin 
Prothiaden (dosulepin) 
Thaden (dosulepin) 
clomipramine 
Anafranil (clomipramine) 
lofepramine 
Gamanil (lofepramine) 
Lomont (lofepramine) 
mianserin 
Bolvidon (mianserin) 
Norval (mianserin) 
chlorpromazine 
cpz - chlorpromazine 
Largactil (chlorpromazine)  
haloperidol 
Haldol (haloperidol) 
Serenace (haloperidol)  
fluphenazine decanoate 
fluphenazine 
Modecate (fluphenazine)  
Moditen tablet (fluphenazine)  
Moditen enanthate 
(fluphenazine) 
flupentixol 
Flupenthixol (flupentixol) 
Depixol (flupentixol) 
Fluanxol (flupentixol) 
zuclopenthixol 
Clopixol (zuclopenthixol)  
loxapine 
Loxapac (loxapine) 
droperidol  
Droleptan (droperidol) 
trifluoperazine 
Stelazine (trifluoperazine)  
thioridazine 
Melleril (thioridazine) 
quetiapine 
Seroquel (quetiapine)  
risperidone 
Risperdal 
(risperidone)  
olanzapine 
Zyprexa (olanzapine) 
aripiprazole 
Abilify (aripiprazole)  
amisulpride 
Solian (amisulpride) 
clozapine  
Clozaril (clozapine) 
diazepam 
diazepam product 
Valium tablet 
(diazepam) 
Valium syrup 
(diazepam) 
Valium supp (diazepam) 
temazepam 
Normison (temazepam) 
Euhypnos (temazepam) 
zopiclone 
Zimovane (zopiclone)  
zaleplon 
Sonata (zaleplon) 
zolpidem 
Stilnoct (zolpidem)  
nitrazepam 
Mogadon (nitrazepam) 
Nitrados (nitrazepam) 
Remnos (nitrazepam) 
Somnite (nitrazepam) 
Noctesed (nitrazepam) 
Surem (nitrazepam) 
Unisomnia (nitrazepam) 
flunitrazepam 
Rohypnol 
(flunitrazepam) 
triazolam 
Halcion (triazolam) 
Methods S1. Detailed description of the cognitive assessments. 
 
Five cognitive measures were administered via computerised touchscreen interface: 
 Reasoning 
Thirteen questions were presented sequentially via touchscreen on a self-paced basis with an 
overall time limit of two minutes. Responses were selected from a multiple-choice array. Any 
questions not attempted during the two-minute time limit were scored as zero. The score for 
analysis was an unweighted total from 0 to 13 (UK Biobank data field 20016, known as the 
‘fluid intelligence’ test), with higher scores indicating better performance. 
 Reaction time 
This test was based on a ‘Snap’-style computer game, in which participants were asked to 
press a button with their dominant hand as quickly as possible each time a matching pair of 
symbols was presented on-screen. Twelve pairs of symbols were presented in total. The score 
for analysis was the mean time (in milliseconds) to press the button, derived from all trials in 
which a matching pair occurred (UK Biobank data field 20023). Higher scores indicate 
slower (i.e. worse) performance. 
 Numeric memory 
A string of numbers was presented on-screen, and after a brief delay participants were asked 
to enter it from memory, in reverse order, via a numeric keypad. Each string was presented 
on screen for a period of 2000ms, plus an additional 500ms multiplied by the string length. A 
delay of 3000ms occurred between clearing the screen and activating the response keypad. 
All participants began with a string length of two, and successive strings increased by one, up 
to a maximum string length of 12. The test was discontinued after five successive incorrect 
responses at a string length of two, or after two successive incorrect responses at string 
lengths of three or more. The score for analysis was the maximum string length recalled 
correctly (UK Biobank data field 4282), with higher scores indicating better performance. 
This task was phased out before recruitment ended for reasons of time, yielding a smaller 
sample size than for the other cognitive measures. 
 Pairs matching 
Pairs of symbols were presented on-screen in a random array. Participants were asked to 
memorise the position of as many matching pairs as possible. The cards were then turned face 
down on the screen and participants were asked to touch as many pairs as possible in the 
fewest tries. The score for analysis was the number of errors made while attempting to select 
the pairs, with a higher score indicating worse performance. Two trials of this task were 
administered, one with three pairs of symbols and one with six pairs. Because of a ceiling 
effect on the three-pair trial, only the score on the six-pair trial of the test was analysed in the 
present study (UK Biobank data field 399.0.2).  
 Prospective memory 
The following instruction appeared on the touchscreen: “At the end of the games we will 
show you four coloured symbols and ask you to touch the blue square. However, to test your 
memory, we want you to actually touch the orange circle instead”. After a delay during which 
participants underwent the other cognitive tasks described above, a screen appeared showing 
four coloured shapes with the instruction to touch the blue square. If the participant touched 
the orange circle, their response was recorded as ‘correct on first attempt’. If they touched the 
blue square, they were given a prompt on-screen to try to recall what the original instruction 
was, and asked to respond again. If they correctly selected the orange circle after receiving 
this prompt, their response was recorded as ‘correct on second attempt’. All other responses 
were recorded as incorrect. For the present analyses, data were dichotomised as either 
‘correct on first attempt’ or not (derived from UK Biobank data field 20018). 
  
Methods S2. Statistical analysis. 
 
Townsend index scores were categorised into quintiles based on frequency to facilitate 
comparisons across groups on the descriptive and unadjusted analyses; quintile 1 represents 
the least deprived and quintile 5 the most deprived areas. The characteristics and cognitive 
performance of each group were summarised using percentages, means and medians, as 
appropriate, and were compared using one-way ANOVA or the Kruskal-Wallis test for 
continuous data, and the Pearson χ2 test for categorical data. Bivariate associations between 
cognitive scores and other characteristics were tested using Pearson χ2 tests, Pearson or 
Spearman correlation tests, t-tests, or Mann-Whitney U-tests, depending on the type and 
distribution of the variables; standardised effect sizes are reported as Pearson’s r, Spearman’s 
ρ, risk ratios (RR), or η2. A natural log transformation was applied to normalise the reaction 
time data, but where results were similar between raw and transformed data, the former are 
reported for ease of interpretation. 
 
Separate univariate regression models were constructed to investigate the relationship 
between mood disorder category and each of the five cognitive measures, followed by a 
series of multivariate models with additional covariates added sequentially. In each 
regression model, the dependent variable was the cognitive measure. The independent 
variable was mood disorder category, which was entered as a categorical variable, with the 
control group as the reference value. The type of regression model used depended on the 
nature and distribution of the cognitive data and the need to address any violation of model 
assumptions. For reasoning, reaction time and numeric memory, linear regression models 
were used, with bootstrapped standard errors to minimise the effect of non-normal residuals 
and heteroscedasticity; results are presented as unstandardised coefficients with 95% 
confidence intervals (CI). The distribution of the pairs matching data was found to be 
significantly positively skewed and leptokurtic, but a log transformation was not advisable 
due to the presence of zero-values in the data. Instead, a negative binomial regression model 
was used (results presented as incidence rate ratios [IRR] with 95% CI). Performance on the 
prospective memory test was coded dichotomously, with 1 representing ‘correct on first 
attempt’ and 0 representing other outcomes (including correct on second attempt and 
incorrect), and a logistic regression model was applied; results are presented as odds ratios 
(OR) with 95% CI. 
 
The first multivariate model (Model 1) adjusted for age and gender. Model 2 also included 
current smoking status (smoker versus non), alcohol use (daily/almost daily versus other) and 
psychotropic medication (yes/no). Current depressive symptoms score was added in Model 3. 
Models 4i and 4ii added degree (yes/no) or Townsend score, respectively, to Model 3; these 
were added separately at this stage in order to allow separate investigation of their effects, 
because they are often conflated. Model 5 was the fully adjusted model and included all the 
covariates in Model 3 plus degree and Townsend score.  
 
The presence of statistically significant interactions between the mood disorder category 
variable and other covariates (age group [decade], gender, degree, psychotropic medication) 
was tested by applying the likelihood ratio test to model estimations with and without an 
interaction term. Where this indicated presence of a significant interaction across the 
cognitive variables, stratified analyses were then carried out to investigate the differential 
effect of the covariate on the regression results. 
 
Analyses were repeated using a narrower control group comprising only participants with no 
mood disorder, for the purpose of comparison. Repeat analyses were also conducted which 
were restricted to only those participants who provided complete data on all the covariates 
(and therefore could be entered in to the final model), in order to explore the potential effect 
of missing data across successive adjusted models.  
  
Results S1. Association between cognitive performance and other variables. 
 
 Age 
Older age was associated with worse performance on all cognitive tests: reasoning r=-0.051; 
reaction time ρ=0.321; numeric memory r=-0.118; pairs matching ρ=0.145; prospective 
memory r=-0.103 (all p<0.001).  
 Gender 
Men scored slightly better than women on all tests (reasoning r=0.058; reaction time r=0.085; 
numeric memory r=0.088; prospective memory risk ratio [RR]=1.02; all p<0.001) except the 
pairs matching task, on which women performed marginally better (r=0.008, p=0.004).  
 Deprivation 
Slightly better performance was seen on all tests in participants with less deprived Townsend 
scores: reasoning ρ=-0.121; reaction time ρ=0.042; numeric memory ρ=-0.063; pairs 
matching ρ=0.011; prospective memory r=-0.097 (all p<0.001).  
 Education 
Having a degree was associated with better cognitive performance: reasoning r=0.307; 
reaction time r=0.089; numeric memory r=0.169; pairs matching r=0.045; prospective 
memory RR=1.11 (all p<0.001).  
 Smoking 
There were differences in performance (p<0.001) associated with smoking status on all tests 
except numeric memory. Current smokers showed relatively lower performance on reasoning 
(mean [SD]: current 5.67 [2.17], former 6.11 [2.11], never 6.07 [2.17]) and prospective 
memory (% correct on first attempt: current 74.9, former 78.5, never 77.1) but relatively 
better performance on pairs matching (error score mean [SD]: current 3.87 [3.26], former 
4.04 [3.25], never 4.04 [3.41]). Former smokers had the slowest reaction time (median [25th, 
75th percentile]: current 543 [484, 622], former 547 [488, 621], never 542 [481, 620]).  
 Alcohol 
Participants who never consume alcohol obtained the poorest scores on all tests (all p<0.001): 
o Reasoning η2 0.034;  
o Reaction time in ms, median (25th, 75th percentile): Never 570 (504, 660); special 
occasions 559 (496, 640); 1-3 times p/month 539 (480, 617); 1-2 times p/week 539 
(480, 617); 3-4 times p/week 535 (480, 610); daily/almost daily 539 (481, 613);  
o Numeric memory η2 0.015;  
o Pairs matching errors, median (25th, 75th percentile): Never 4 (2, 6); special 
occasions 3 (2, 6); each other group 3 (2, 5);   
o Prospective memory % correct on first attempt: Never 64.4; special occasions 69.7; 
1-3 times p/month 78.3; 1-2 times p/week 77.4; 3-4 times p/week 81.2; daily/almost 
daily 81.8. 
 Psychotropic medication 
Consumption of any psychotropic medication was weakly associated with poorer 
performance: reasoning r=-0.038; reaction time r=0.036; numeric memory r=-0.041; pairs 
matching r=0.016; prospective memory RR=0.93 (all p<0.001).  
 Current depressive symptoms  
Higher current depressive symptom scores were associated with slightly worse performance 
on all tests except pairs matching: reasoning ρ=-0.056; reaction time r=0.016; numeric 
memory ρ=-0.034; prospective memory r=-0.037 (all p<0.001).  
 Neuroticism  
Higher neuroticism scores were similarly associated with slightly poorer performance: 
reasoning r=-0.059; reaction time ρ=0.011; numeric memory r=-0.043; pairs matching 
ρ=0.017; prospective memory r=-0.036 (all p<0.001).  
  
 
 
Figure S1. Sample composition. 
 
a. Participants self-reported one or more neurological conditions which can potentially affect 
cognitive performance (see Appendix S1 for full list). 
  
Table S1. Regression models for the association between lifetime mood disorder features and cognitive performance. 
 
 Unadjusted Model 1a Model 2b Model 3c Model 4id Model 4iie Model 5f 
 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Coefficient 
(95% CI) p 
Reasoning 
scoreg 
n = 139 140  n = 139 140  n = 137 377  n = 126 796  n = 126 000  n = 126 584  n = 125 789  
Single 
episode major 
depression 
0.27 
(0.23, 0.31) <.001 
0.30 
(0.25, 0.34) <.001 
0.31 
(0.27, 0.36) <.001 
0.31 
(0.26, 0.35) <.001 
0.27 
(0.23, 0.32) <.001 
0.30 
(0.25, 0.35) <.001 
0.26 
(0.22, 0.31) <.001 
Recurrent 
major 
depression 
(moderate) 
0.08 
(0.05, 0.12) <.001 
0.11 
(0.08, 0.14) <.001 
0.16 
(0.12, 0.20) <.001 
0.26 
(0.22, 0.29) <.001 
0.22 
(0.19, 0.26) <.001 
0.25 
(0.21, 0.30) <.001 
0.22 
(0.18, 0.26) <.001 
Recurrent 
major 
depression 
(severe) 
-0.12 
(-0.17, -0.07) <.001 
-0.12 
(-0.17, -0.06) <.001 
0.01 
(-0.04, 0.05) .758 
0.18 
(0.12, 0.23) <.001 
0.09 
(0.03, 0.14) .002 
0.21 
(0.15, 0.27) <.001 
0.12 
(0.07, 0.17) <.001 
Bipolar 
disorder 
-0.27 
-0.38, -0.17) <.001 
-0.32 
(-0.41, -0.22) <.001 
-0.18 
(-0.32, -0.04) .012 
0.04 
(-0.08, 0.17) .488 
-0.03 
(-0.13, 0.08) .625 
0.11 
(-0.02, 0.23) .087 
0.04 
(-0.06, 0.13) .442 
Reaction 
time (ms)g n = 142 335  n = 142 335  n = 140 501  n = 129 242  n = 128 320  n = 129 025  n = 128 104  
Single 
episode major 
depression 
-6.59 
(-9.41, -3.77) <.001 
-6.21 
(-8.56, -3.87) <.001 
-6.80 
(-9.18, -4.42) <.001 
-6.09 
(-8.94, -3.23) <.001 
-5.76 
(-8.82, -2.69) <.001 
-5.78 
(-8.28, -3.28) <.001 
-5.47 
(-8.19, -2.75) <.001 
Recurrent 
major 
depression 
(moderate) 
-4.96 
(-7.11, -2.81) <.001 
-1.85 
(-3.95, 0.25) .084 
-3.92 
(-6.10, -1.73) <.001 
-6.70 
(-9.00, -4.41) <.001 
-6.28 
(-8.29, -4.26) <.001 
-6.64 
(-8.62, -4.66) <.001 
-6.24 
(-8.29, -4.20) <.001 
Recurrent 
major 
depression 
(severe) 
4.12 
(1.52, 6.72) .002 
8.48 
(5.13, 11.83) <.001 
3.55 
(0.39, 6.71) .028 
-0.51 
(-3.08, 2.07) .700 
0.32 
(-2.78, 3.41) .842 
-1.64 
(-4.23, 0.96) .216 
-0.82 
(-3.39, 1.75) .530 
  
 Unadjusted Model 1a Model 2b Model 3c Model 4id Model 4iie Model 5f 
Bipolar 
disorder 
2.37 
(-5.28, 10.02) .543 
13.93 
(7.17, 20.70) <.001 
8.67 
(1.91, 15.44) .012 
3.48 
(-2.53, 9.49) .257 
4.06 
(-0.83, 8.95) .104 
1.15 
(-5.43, 7.72) .733 
1.70 
(-5.11, 8.51) .625 
Numeric 
memory 
scoreg 
n = 42 245h  n = 42 245h  n = 41 580h  n = 38 426h  n = 38 151h  n = 38 325h  n = 38 051h  
Single 
episode major 
depression 
0.07  
(0.01, 0.13) .015 
0.08 
(0.03, 0.13) .001 
0.09 
(0.03, 0.16) .003 
0.09 
(0.03, 0.15) .002 
0.07 
(0.02, 0.13) .009 
0.09 
(0.04, 0.14) <.001 
0.07  
(0.02, 0.12) .004 
Recurrent 
major 
depression 
(moderate) 
0.00  
(-0.04, 0.04) .868 
0.01 
(-0.03, 0.05) .644 
0.04 
(-0.00, 0.08) .054 
0.07 
(0.02, 0.12) .003 
0.06 
(0.02, 0.10) .006 
0.08 
(0.04, 0.11) <.001 
0.06  
(0.02, 0.11) .004 
Recurrent 
major 
depression 
(severe) 
-0.08  
(-0.14, -0.02) .006 
-0.09 
(-0.15, -0.03) .002 
-0.03 
(-0.10, 0.04) .364 
0.04 
(-0.02, 0.11) .175 
0.01 
(-0.04, 0.06) .687 
0.05 
(-0.02, 0.12) .126 
0.02  
(-0.04, 0.08) .505 
Bipolar 
disorder 
-0.10  
(-0.26, 0.07) .267 
-0.15 
(-0.29, -0.01) .035 
-0.06 
(-0.19, 0.07) .354 
0.04 
(-0.12, 0.21) .596 
0.01 
(-0.14, 0.16) .860 
0.07 
(-0.08, 0.22) .383 
0.03  
(-0.10, 0.16) .606 
 
IRR 
(95% CI) p 
IRR 
(95% CI) p 
IRR 
(95% CI) p 
IRR 
(95% CI) p 
IRR 
(95% CI) p 
IRR 
(95% CI) p 
IRR 
(95% CI) p 
Pairs 
matching 
(errors)i 
n = 143 828  n = 143 828  n = 141 964  n = 130 413  n = 129 446  n = 130 195  n = 129 229  
Single 
episode major 
depression 
0.97  
(0.95, 0.98) <.001 
0.98  
(0.96, 0.99) .008 
0.97  
(0.95, 0.99) .002 
0.97  
(0.95, 0.99) .004 
0.97  
(0.96, 0.99) .007 
0.97  
(0.96, 0.99) .005 
0.98  
(0.96, 0.99) .009 
Recurrent 
major 
depression 
(moderate) 
0.98  
(0.97, 0.99) .023 
1.01  
(0.99, 1.02) .452 
1.00  
(0.99, 1.02) .852 
0.99  
(0.98, 1.01) .259 
0.99  
(0.98, 1.01) .385 
0.99  
(0.98, 1.01) .301 
0.99  
(0.98, 1.01) .428 
  
 Unadjusted Model 1a Model 2b Model 3c Model 4id Model 4iie Model 5f 
Recurrent 
major 
depression 
(severe) 
1.04  
(1.02, 1.06) <.001 
1.06  
(1.04, 1.08) <.001 
1.05  
(1.03, 1.07) <.001 
1.03  
(1.01, 1.05) .001 
1.04  
(1.02, 1.06) <.001 
1.03  
(1.01, 1.05) .002 
1.03  
(1.02, 1.05) <.001 
Bipolar 
disorder 
1.04  
(0.99, 1.08) .085 
1.08  
(1.04, 1.12) <.001 
1.07  
(1.03, 1.11) .001 
1.04  
(0.99, 1.08) .076 
1.04  
(1.00, 1.09) .045 
1.03  
(0.99, 1.07) .148 
1.04  
(0.99, 1.08) .095 
 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
OR 
(95% CI) p 
Prospective 
memory 
(correct 1st 
attempt)j 
n = 143 136  n = 143 136  n = 141 288  n = 129 885  n = 128 944  n = 129 667  n = 128 727  
Control group 
(reference) 1 - 1 - 1 - 1 - 1 - 1 - 1 - 
Single 
episode major 
depression 
1.39  
(1.31, 1.48) <.001 
1.38 
(1.30, 1.47) <.001 
1.41 
(1.32, 1.50) <.001 
1.41 
(1.32, 1.50) <.001 
1.38 
(1.29, 1.47) <.001 
1.40 
(1.31, 1.49) <.001 
1.37  
(1.28, 1.47) <.001 
Recurrent 
major 
depression 
(moderate) 
1.15  
(1.10, 1.20) <.001 
1.12 
(1.07, 1.17) <.001 
1.17 
(1.12, 1.22) <.001 
1.27 
(1.21, 1.33) <.001 
1.25 
(1.19, 1.31) <.001 
1.26 
(1.20, 1.32) <.001 
1.25  
(1.19, 1.31) <.001 
Recurrent 
major 
depression 
(severe) 
0.91  
(0.87, 0.96) <.001 
0.88 
(0.83, 0.93) <.001 
0.97 
(0.92, 1.02) .261 
1.12 
(1.05, 1.18) <.001 
1.08 
(1.02, 1.15) .012 
1.15 
(1.08, 1.22) <.001 
1.11  
(1.05, 1.18) .001 
Bipolar 
disorder 
0.84  
(0.75, 0.94) .003 
0.77 
(0.68, 0.86) <.001 
0.86 
(0.76, 0.96) .010 
1.01 
(0.89, 1.14) .915 
0.98 
(0.86, 1.12) .781 
1.07 
(0.94, 1.22) .293 
1.05  
(0.92, 1.19) .501 
 
CI, confidence interval; IRR, incidence rate ratio; OR, odds ratio. 
a. Adjusted for age, gender. 
b. Adjusted for age, gender, current smoker, alcohol daily/almost daily, on psychotropic medication. 
c. Adjusted for age, gender, current smoker, alcohol daily/almost daily, on psychotropic medication, current depressive symptoms score. 
d. Adjusted for age, gender, current smoker, alcohol daily/almost daily, on psychotropic medication, current depressive symptoms score, has a degree. 
e. Adjusted for age, gender, current smoker, alcohol daily/almost daily, on psychotropic medication, current depressive symptoms score, Townsend score. 
f. Adjusted for age, gender, current smoker, alcohol daily/almost daily, on psychotropic medication, current depressive symptoms score, has a degree, Townsend score. 
  
g. Linear regression with bootstrapped standard errors; omitted reference group was the control group. 
h. The Numeric Memory task was removed from the baseline battery before recruitment ended, yielding smaller possible sample sizes than for the other cognitive measures. 
i. Negative binomial regression; omitted reference group was the control group. 
j. Logistic regression. 
 
